Dr. Gearóid Tuohy

FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)

SPK-RPE65, a novel gene therapy undergoing development for the treatment of nyctalopia, has received “breakthrough therapy designation” from the FDA. The drug’s sponsor, Spark Therapeutics,… Read More »FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)